Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. This article will focus on Sanofi Diabetes. In August 2014, our previous article “Sanofi buys Mannkind’s inhaled insulin for €824.5m” suggested that Sanofi may launch the first ever inhaled insulin in 2015. It’s now done! The U.S. Food and Drug Administration (FDA) approved Toujeo, a long-acting basal insulin patients have to inhale only once a day, enabling type 1 and type 2 diabetes sufferes to control their glycemic level .
John Anderson, MD, internal medicine and diabetes specialist, Frist Clinic of Nashville, TN, and Past President of the American Diabetes Association, said:“Nearly 50 percent of people living with diabetes remain uncontrolled. Despite the proven efficacy of insulin, ensuring effective titration and maintenance can be a challenge for both patients and healthcare professionals due to hypoglycemia concerns. Toujeo provides a new option that may help patients manage their diabetes.”
The approval of Toujeo was based on the FDA’s review of the results of the EDITION clinical trial program,